NASDAQ:CLBS
Delisted
Caladrius Biosciences Stock News
$3.55
+0.0399 (+1.14%)
At Close: Jan 27, 2023
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
02:15pm, Wednesday, 12'th May 2021
Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the N
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript
03:18am, Friday, 07'th May 2021
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q1 2021 Results - Earnings Call Transcript
Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates
08:17pm, Thursday, 06'th May 2021
Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of -111.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for t
Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. Eastern Time
08:30am, Thursday, 29'th Apr 2021
BASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d
Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?
09:51am, Monday, 08'th Mar 2021
Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.
Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?
12:55pm, Thursday, 04'th Mar 2021
Caladrius Biosciences, Inc. (CLBS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
08:30am, Wednesday, 03'rd Mar 2021
BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2020 Results - Earnings Call Transcript
05:44am, Friday, 26'th Feb 2021
Caladrius Biosciences, Inc. (CLBS) CEO David Mazzo on Q4 2020 Results - Earnings Call Transcript
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
04:05pm, Thursday, 25'th Feb 2021
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing
BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de
Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
01:59pm, Wednesday, 17'th Feb 2021
BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
08:15am, Friday, 12'th Feb 2021
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
01:54pm, Friday, 05'th Feb 2021
Longeveron Seeks $25 Million IPO For Anti-Aging Efforts
Caladrius Biosciences Closes $25.0 Million Private Placement
05:05pm, Monday, 25'th Jan 2021
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the de
Caladrius Biosciences Announces Participation in Upcoming Virtual Conferences in February 2021
08:30am, Monday, 25'th Jan 2021
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the d